Comparative Effects of Autogenic Inhibition and Reciprocal Inhibition Technique on Pain, Functional Disability and Gait in Sacroiliac Joint Dysfuction.

May 14, 2026 updated by: Foundation University Islamabad
Sacro-iliac joint act as the shock absorber of the body. It is responsible for transferring vertical load of the whole body to lower limb hence contributing to stability of pelvic girdle. However, SI joint dysfunction is one of the most common causes of low back pain among the patients suffering from non-radicular low back pain. There can be a mechanical source which is due to muscle insufficiency or instability or a non-mechanical source which is osteoarthritis, infection or any trauma. It is thought to affect females more commonly with prevalence of about 46.71% in females and with the prevalence of about 15 to 30% in general. This poses great threat to bio mechanics of the body which can significantly lead to disability that can affect mobility, daily activities and quality of life of the individual. According to a study the pain caused by SIJD caused activity limitation and participation restriction of about 25% of the individuals. Hence making it difficult for them to continue their jobs. increased pain leads to worsening of the ability to perform ADLs which ultimately effects the quality of life. Altered biomechanics also leads to alteration in spatio temporal gait parameters.This study aims to compare the effects of autogenic inhibition technique and reciprocal inhibition technique in addition with conventional therapy in reliving low back pain, improving functional disability and alteration in spatio-temporal gait parameters in patients with sacroiliac joint dysfunction. Patients with SIJD will be recruited and will be randomly divided into two groups 20 in each group. Group 1 will receive autogenic inhibition technique of iliopsas, hamstrings, erector spinae and piriformis muscles along with standard core stabilization exercises and group 2 will receive reciprocal inhibition technique on iliopsas, hamstrings, erector spinae and piriformis muscles along with standard core stabilization exercises. The treatment will be continued for 3 weeks with 4 sessions of 25 minutes per week.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Participants will be divided into two groups and a total of 12 sessions will be given for 3 weeks with a frequency of 4 sessions per week and a duration of 25 minutes. Group 1 will be given autogenic inhibition technique of iliopsoas, Piriformis, hamstrings and erector spinae along with core stability exercises and conentional therapy. Group 2 will be given reciprocal inhibition techniques of iliopsoas, Piriformis, hamstrings and erector spinae along with conventional treatment and core stability exercises.

Group 1 Group 2 WEEK 1 4 SESSEIONS/ WEEK

  • TENS + hot pack ⇢10 mins
  • drawing in maneuver in quadruped position ⇢7 reps ⇢3 sec hold
  • Bridiging ⇢5 reps ⇢no hold
  • PIR of illiopsoas ⇢5 reps ⇢10 sec hold
  • PIR of PIRiformis ⇢5 reps ⇢10 sec hold
  • PIR of hamstrings ⇢5 reps ⇢10 sec hold
  • PIR of erector spinae ⇢5 reps ⇢10 sec hold • TENS + hot pack ⇢10 mins
  • drawing in maneuver in quadruped position ⇢7 reps ⇢3 sec hold
  • Bridiging ⇢5 reps ⇢no hold
  • RI-MET of illiopsoas ⇢5 reps ⇢10 sec hold
  • RI-MET of PIRiformis ⇢5 reps ⇢10 sec hold
  • RI-MET of hamstrings ⇢5 reps ⇢10 sec hold
  • RI-MET of erector spinae ⇢5 reps ⇢10 sec hold Group 1 Group 2 WEEK 2 4 SESSEIONS/ WEEK
  • TENS + hot pack ⇢10 mins
  • drawing in manuver in quadruped position ⇢7 reps ⇢6 sec hold
  • Bridiging ⇢5reps ⇢3 sec hold
  • Clam shell exercises ⇢6 reps
  • PIR of illiopsoas ⇢7 reps ⇢10 sec hold
  • PIR of PIRiformis ⇢7 reps ⇢10 sec hold
  • PIR of hamstrings ⇢ 7 reps ⇢10 sec hold
  • PIR of erector spinae ⇢7 reps ⇢10 sec hold • TENS + hot pack ⇢10 mins
  • drawing in manuver in quadruped position ⇢7 reps ⇢6 sec hold
  • Bridiging ⇢5reps ⇢3 sec hold
  • Clam shell exercises ⇢6 reps
  • RI-MET of illiopsoas ⇢7 reps ⇢10 sec hold
  • RI-MET of PIRiformis ⇢7 reps ⇢10 sec hold
  • RI-MET of hamstrings ⇢ 7 reps ⇢10 sec hold
  • RI-MET of erector spinae ⇢7 reps ⇢10 sec hold

Group 1 Group 2 WEEK 3 4 SESSEIONS/ WEEK

  • TENS + hot pack ⇢10 mins
  • drawing in manuver in quadruped position ⇢8 reps ⇢8 sec hold
  • Supine Bridiging ⇢10 reps ⇢ 6 sec hold
  • Clam shell exercises ⇢10 reps ⇢6 sec hold
  • PIR of illiopsoas ⇢10 reps ⇢10 sec hold
  • PIR of PIRiformis ⇢10 reps ⇢10 sec hold
  • PIR of hamstrings ⇢10 reps ⇢ 10 sec hold
  • PIR of erector spinae ⇢ 10 reps ⇢10 sec hold
  • TENS + hot pack ⇢10 mins
  • drawing in manuver in quadruped position ⇢8 reps ⇢8 sec hold
  • Supine Bridiging ⇢10 reps ⇢ 6 sec hold
  • Clam shell exercises ⇢10 reps ⇢6 sec hold
  • RI-MET of illiopsoas ⇢10 reps ⇢10 sec hold
  • RI-MET of PIRiformis ⇢10 reps ⇢10 sec hold
  • RI-MET of hamstrings ⇢10 reps ⇢ 10 sec hold
  • RI-MET of erector spinae ⇢ 10 reps ⇢10 sec hold

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Pakistan
    • Punjab Province
      • Islamabad, Punjab Province, Pakistan, 44000
        • Recruiting
        • Foundation University College of Physical Therapy
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients having low back pain greater than 4 weeks
  • Patients with positive gaenslen's test, thigh thurst test, standing flexion test, sacral compression and distraction test.
  • Patients not having any other condition that can affect gait
  • 25-45 years
  • Both males and females

Exclusion Criteria:

  • Patients having nonspecific low back
  • Patients with lumbosacral fusion
  • Patients with any neurological condition
  • Patients with history of trauma of spine
  • Patients with any other lumbar spine condition (lumbar radiculopathy, spinal stenosis, spondylolisthesis, inflammatory arthritis)
  • Patients with any hip joint pathology
  • Patients using any assistive device

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Autogenic Inhibition Technique

During week 1, group 1 will receive TENS + hot pack ⇢10 mins Drawing in maneuver in quadruped position ⇢7 reps ⇢3 sec hold Bridiging ⇢5 reps ⇢no hold PIR of illiopsoas ⇢5 reps ⇢10 sec hold PIR of PIRiformis ⇢5 reps ⇢10 sec hold PIR of hamstrings ⇢5 reps ⇢10 sec hold PIR of erector spinae ⇢5 reps ⇢10 sec hold

During week 2, group 1 will receive TENS + hot pack ⇢10 mins Drawing in manuver in quadruped position ⇢7 reps ⇢6 sec hold Bridiging ⇢5reps ⇢3 sec hold Clam shell exercises ⇢6 reps PIR of illiopsoas ⇢7 reps ⇢10 sec hold PIR of PIRiformis ⇢7 reps ⇢10 sec hold PIR of hamstrings ⇢ 7 reps ⇢10 sec hold PIR of erector spinae ⇢7 reps ⇢10 sec hold

During week 3, group 1 will receive TENS + hot pack ⇢10 mins Drawing in manuver in quadruped position ⇢8 reps ⇢8 sec hold Supine Bridiging ⇢10 reps ⇢ 6 sec hold Clam shell exercises ⇢10 reps ⇢6 sec hold PIR of illiopsoas ⇢10 reps ⇢10 sec hold PIR of PIRiformis ⇢10 reps ⇢10 sec hold PIR of hamstrings ⇢10 reps ⇢ 10 sec
Procedure: Autogenic Inhibition
During week 1, group 1 will receive TENS + hot pack ⇢10 mins Drawing in maneuver in quadruped position Bridiging PIR of illiopsoas,Piriformis, hamstrings,erector spinae During week 2, group 1 will receive TENS + hot pack ⇢10 mins Drawing in manuver in quadruped position Bridiging Clam shell exercises PIR of illiopsoas, PIRiformis, hamstrings, erector spinae During week 3, group 1 will receive TENS + hot pack ⇢10 mins Drawing in manuver in quadruped position Supine Bridiging, Clam shell exercises, PIR of illiopsoas PIR of Piriformis, hamstrings and erector spinae
Experimental: Reciprocal Inhibition Technique

During week 1, group 2 will receive TENS + hot pack ⇢10 mins Drawing in maneuver in quadruped position ⇢7 reps ⇢3 sec hold Bridiging ⇢5 reps ⇢no hold RI-MET of illiopsoas ⇢5 reps ⇢10 sec hold RI-MET of PIRiformis ⇢5 reps ⇢10 sec hold RI-MET of hamstrings ⇢5 reps ⇢10 sec hold RI-MET of erector spinae ⇢5 reps ⇢10 sec hold

During week 2, group 2 will receive TENS + hot pack ⇢10 mins Drawing in manuver in quadruped position ⇢7 reps ⇢6 sec hold Bridiging ⇢5reps ⇢3 sec hold Clam shell exercises ⇢6 reps RI-MET of illiopsoas ⇢7 reps ⇢10 sec hold RI-MET of PIRiformis ⇢7 reps ⇢10 sec hold RI-MET of hamstrings ⇢ 7 reps ⇢10 sec hold RI-MET of erector spinae ⇢7 reps ⇢10 sec hold

During week 3, group 2 will receive TENS + hot pack ⇢10 mins drawing in manuver in quadruped position ⇢8 reps ⇢8 sec hold Supine Bridiging ⇢10 reps ⇢ 6 sec hold Clam shell exercises ⇢10 reps ⇢6 sec hold RI-MET of illiopsoas ⇢10 reps ⇢10 sec hold RI-MET of PIRiformis ⇢10 reps ⇢10 sec hold RI-MET o
Procedure: Reciprocal Inhibition
During week 1, group 2 will receive TENS + hot pack ⇢10 mins Drawing in maneuver in quadruped position ⇢7 reps ⇢3 sec hold Bridiging ⇢5 reps ⇢no hold RI-MET of illiopsoas, PIRiformis, hamstrings, erector spinae ⇢5 reps ⇢10 sec hold During week 2, group 2 will receive TENS + hot pack ⇢10 mins Drawing in manuver in quadruped position ⇢7 reps ⇢6 sec hold Bridiging ⇢5reps ⇢3 sec hold Clam shell exercises ⇢6 reps RI-MET of illiopsoas, PIRiformis, hamstrings, erector spinae ⇢7 reps ⇢10 sec hold During week 3, group 2 will receive TENS + hot pack ⇢10 mins drawing in manuver in quadruped position ⇢8 reps ⇢8 sec hold Supine Bridiging, Clam shell exercises ⇢10 reps ⇢6 sec hold RI-MET of illiopsoas, Piriformis, erector spinae ⇢10 reps ⇢10 sec hold

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Functional disability
Time Frame: before treatment after after 3 weeks
It will be measured by using Denver SI joint disability questionnaire which 10 questions questionnaire consisting of scoring range from 0-5 in each item answered. 0 means no disability and 5 means maximum disability. And total score is calculated in the form of percentage. Higher the percentage greater is the disability.
before treatment after after 3 weeks
Pain intensity
Time Frame: before treatment and after 3 weeks
Pain will be measured by NPRS. A line of 10 centimeters containing numbers from 0 to 10 marked. The starting point of the scale indicates 0 or no pain whereas the ending point marks the pain as 10 which means the pain is as worse as it could be.
before treatment and after 3 weeks
Gait Speed
Time Frame: Assessed at baseline (before intervention) and after 3 weeks of intervention.

Gait speed will be measured by calculating the distance covered in meters divided by the time taken in seconds during walking assessment.

Formula: Gait Speed (m/s) = Distance (m) × Time (s)
Assessed at baseline (before intervention) and after 3 weeks of intervention.
Cadance
Time Frame: Assessed at baseline (before intervention) and after 3 weeks of intervention.

Cadence will be measured as the number of steps taken per minute during walking assessment.

Formula: Cadence (steps/min) = Steps Counted × 60 / Time (s)
Assessed at baseline (before intervention) and after 3 weeks of intervention.
Cycle time
Time Frame: Assessed at baseline (before intervention) and after 3 weeks of intervention.

Cycle time will be calculated as the time required to complete one gait cycle during walking assessment.

Formula: Cycle Time (s) = Time (s) × 2 / Steps Counted
Assessed at baseline (before intervention) and after 3 weeks of intervention.
Stride Length
Time Frame: Assessed at baseline (before intervention) and after 3 weeks of intervention.

Stride length will be determined by multiplying gait speed with cycle time during walking assessment.

Formula: Stride Length (m) = Speed (m/s) × Cycle Time (s)
Assessed at baseline (before intervention) and after 3 weeks of intervention.
Step Length
Time Frame: Assessed at baseline (before intervention) and after 3 weeks of intervention.

Step length will be calculated as half of the stride length obtained during gait assessment.

Formula: Step Length (m) = Stride Length / 2
Assessed at baseline (before intervention) and after 3 weeks of intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Foundation University Islamabad

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Fajar Sajjad, DPT, Foundation University Islamabad

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 15, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 15, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 14, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 14, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 20, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 20, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 14, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • FUI/FUCP/CTR/10.26/FajarSajad

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sacroiliac Joint Dysfunction

Clinical Trials on Autogenic Inhibition

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings